Barone Francesca
Chief Scientific Officer
Barone Francesca has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Jul 1, 2026.
On the most recent filing, Barone Francesca is listed as Chief Scientific Officer at Candel Therapeutics, Inc. Inside the rolling window, Barone Francesca reported no open-market purchases and 1 open-market sale totaling $236K in CADL.
Companies traded
Other insiders at CADL
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$236K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Barone Francesca made?
Barone Francesca has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2026.
Which companies does Barone Francesca trade?
Barone Francesca has filed SEC Form 4 disclosures for 1 company, including CADL.
When was Barone Francesca's most recent SEC Form 4 filing?
Barone Francesca's most recent SEC Form 4 filing on Tracefour is dated Jul 1, 2026.
What is Barone Francesca's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Barone Francesca is listed as Chief Scientific Officer.
What is Barone Francesca's total buy and sell value in the current window?
Inside the rolling retention window, Barone Francesca bought $0 and sold $236K based on SEC Form 4 filings.
What was Barone Francesca's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 23,447 CADL shares on 2026-06-29, worth $236K, per SEC Form 4 filings.